Business · 25/02/2019
FDA Reopens Comment Period for Proposed Rule on Institutional Review Board Waiver or Alteration of Informed Consent
The Food and Drug Administration is reopening the comment period for a proposed rule related to Institutional Review Board waiver or alteration of informed consent for minimal risk clinical investigations, following technical issues with the Federal eRulemaking Portal.